CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer

Παρόμοια τεκμήρια

• A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma
  ανά: Zhu, Ji, κ.ά.
  Έκδοση: (2013)
• A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer
  ανά: Willeke, F, κ.ά.
  Έκδοση: (2007)
• An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy for locally advanced rectal cancer with UGT1A1 *1*1 genotype
  ανά: Guan, Yun, κ.ά.
  Έκδοση: (2019)
• Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study
  ανά: Zhu, Ji, κ.ά.
  Έκδοση: (2014)
• RTOG 0247: A Randomized Phase II Study of Neoadjuvant Capecitabine and Irinotecan or Capecitabine and Oxaliplatin with Concurrent Radiation Therapy for Patients with Locally Advanced Rectal Cancer
  ανά: Wong, Stuart J., κ.ά.
  Έκδοση: (2011)